These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3281057)

  • 1. No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
    Mouradian MM; Mohr E; Williams JA; Chase TN
    Neurology; 1988 Apr; 38(4):606-8. PubMed ID: 3281057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
    Bruno G; Mohr E; Gillespie M; Fedio P; Chase TN
    Arch Neurol; 1986 Jul; 43(7):659-61. PubMed ID: 3524514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).
    Wettstein A; Spiegel R
    Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.
    Hollander E; Davidson M; Mohs RC; Horvath TB; Davis BM; Zemishlany Z; Davis KL
    Biol Psychiatry; 1987 Sep; 22(9):1067-78. PubMed ID: 3651528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.
    Foster NL; Aldrich MS; Bluemlein L; White RF; Berent S
    Neurology; 1989 Feb; 39(2 Pt 1):257-61. PubMed ID: 2644580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinergic approaches to the treatment of Alzheimer's disease.
    Hollander E; Mohs RC; Davis KL
    Br Med Bull; 1986 Jan; 42(1):97-100. PubMed ID: 3006861
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cerebral glucose metabolism in presenile dementia of the Alzheimer type--follow-up of therapy with muscarinergic choline agonists].
    Szelies B; Herholz K; Pawlik G; Beil C; Wienhard K; Heiss WD
    Fortschr Neurol Psychiatr; 1986 Nov; 54(11):364-73. PubMed ID: 3492415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-dose arecoline infusions in Alzheimer's disease.
    Tariot PN; Cohen RM; Welkowitz JA; Sunderland T; Newhouse PA; Murphy DL; Weingartner H
    Arch Gen Psychiatry; 1988 Oct; 45(10):901-5. PubMed ID: 3048224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of mania with the cholinomimetic agent RS 86.
    Krieg JC; Berger M
    Br J Psychiatry; 1986 May; 148():613. PubMed ID: 3535973
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusion of neostigmine-glycopyrrolate for bowel evacuation in persons with spinal cord injury.
    Korsten MA; Rosman AS; Ng A; Cavusoglu E; Spungen AM; Radulovic M; Wecht J; Bauman WA
    Am J Gastroenterol; 2005 Jul; 100(7):1560-5. PubMed ID: 15984982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials.
    Penn RD; Martin EM; Wilson RS; Fox JH; Savoy SM
    Neurology; 1988 Feb; 38(2):219-22. PubMed ID: 2893314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Zemlan FP
    J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GABA-agonist therapy for Alzheimer's disease.
    Mohr E; Bruno G; Foster N; Gillespie M; Cox C; Hare TA; Tamminga C; Fedio P; Chase TN
    Clin Neuropharmacol; 1986; 9(3):257-63. PubMed ID: 2872956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.
    Raffaele KC; Berardi A; Asthana S; Morris P; Haxby JV; Soncrant TT
    Psychopharmacol Bull; 1991; 27(3):315-9. PubMed ID: 1775605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid with or without vitamin B12 for cognition and dementia.
    Malouf M; Grimley EJ; Areosa SA
    Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic frontiers in Alzheimer's disease.
    Miller SW; Mahoney JM; Jann MW
    Pharmacotherapy; 1992; 12(3):217-31. PubMed ID: 1608856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.